SF
GILD icon

Summit Financial’s Gilead Sciences GILD Stock Holding History

Summit Financial’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.48M Buy
32,149
+1,777
+6% +$249K 0.06% 343
2025
Q4 		$3.73M Buy
30,372
+2,999
+11% +$364K 0.05% 327
2025
Q3 		$3.04M Buy
27,373
+2,567
+10% +$292K 0.05% 370
2025
Q2 		$2.75M Buy
24,806
+3,913
+19% +$416K 0.06% 248
2025
Q1 		$2.34M Buy
20,893
+1,459
+8% +$151K 0.07% 236
2024
Q4 		$1.8M Buy
19,434
+15,484
+392% +$1.39M 0.06% 229
2024
Q3 		$331K Buy
3,950
+87
+2% +$6.64K 0.01% 442
2024
Q2 		$265K Buy
+3,863
New +$258K 0.01% 438

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Summit Financial's GILD Position: Q1 2026 in Review

Summit Financial increased its Gilead Sciences (GILD) stake by 5.9% in Q1 2026, buying an estimated $249K and bringing the position to 32,149 shares worth $4.48M. The position accounts for 0.06% of the portfolio, ranked #343.

Summit Financial first reported a position in GILD in Q2 2024 and has held it in 8 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Summit Financial held 32,149 shares of Gilead Sciences worth $4.48M as of Q1 2026.
  • Summit Financial bought 1,777 Gilead Sciences shares in Q1 2026, an estimated $249K.
  • Gilead Sciences made up 0.06% of Summit Financial's portfolio in Q1 2026, its #343 holding.
  • Summit Financial first reported a position in Gilead Sciences in Q2 2024 and has held it in 8 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Summit Financial's 13F filing for Q1 2026, filed 15 May 2026.